Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis - The Journal of Allergy and Clinical Immunology: In Practice
Example of case before and after treatment with dupilumab 300mg every... | Download Scientific Diagram
Abrocitinib as a treatment option for atopic dermatitis | DDDT
Profile of dupilumab and its potential in the treatment of inadequatel | CCID
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial - The Lancet
Dupixent (dupilumab) for the Treatment of Atopic Dermatitis
Clinical efficacy of Phase III trials of dupilumab for adult with... | Download Scientific Diagram
Figure 1 from Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. | Semantic Scholar
View Image
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial - Journal of the American Academy of Dermatology
Drug evaluation review: dupilumab in atopic dermatitis | Immunotherapy
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III
Pfizer's abrocitinib non-inferior to Sanofi's Dupixent in atopic dermatitis < Pharma < 기사본문 - KBR
Dupixent (dupilumab) for the Treatment of Atopic Dermatitis
Sanofi, Regeneron's Dupixent aces late-stage study in young children with atopic dermatitis | Fierce Pharma
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease | Nature Reviews Drug Discovery
JCM | Free Full-Text | Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis | HTML
dupilumab for Dermatitis Clinical Trial | Power
Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis - The Journal of Allergy and Clinical Immunology: In Practice
Drug evaluation review: dupilumab in atopic dermatitis. | Semantic Scholar
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) - Journal
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial - Journal of the American
Modify treatment for atopic dermatitis when patient response to dupilumab is partial or non-durable | SpringerLink
A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis,Allergy - X-MOL
